ImmuPharma (IMM) News Today

ImmuPharma plc (LON:IMM) shares have climbed sharply this week after key patent news drove a wave of buying interest. A UK patent grant for its lupus drug candidate underpinned a series of intraday gains—peaking at 34.1%—and trading volumes surged well above average as investors speculated on the treatment’s commercial potential.

• Positive Sentiment: UK patent granted for ImmuPharma’s lead lupus therapy, enhancing its competitive position and commercial outlook SMALL CAP MOVERS: Lupus drug patent lights up the market
• Positive Sentiment: Shares recorded successive intraday jumps of 34.1%, 22.1%, 17.2% and 13.9% amid heavy buying interest IMM Stock Price Up 17.2% - Here's Why
• Neutral Sentiment: Trading volume jumped to over 44 million shares, well above the 50-day average of 8 million, signaling heightened investor interest
• Negative Sentiment: Despite the rally, ImmuPharma remains unprofitable—trading at a P/E of -1,570.67 with analysts forecasting a -339 EPS for the current fiscal year